Patents Represented by Attorney Kathryn L. Sieburth
  • Patent number: 8093255
    Abstract: This invention relates to imidazopyrimidine substituted piperidine derivatives and their use as pharmaceuticals.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: January 10, 2012
    Assignee: Glaxo Group Limited
    Inventors: Giuseppe Alvaro, David Amantini, Sandro Belvedere
  • Patent number: 8012981
    Abstract: The invention relates to compounds of formula (I): processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the GPR38 receptor.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: September 6, 2011
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Thomas Seal, Geoffrey Stemp, Mervyn Thompson, Susan Marie Westaway
  • Patent number: 7977337
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: July 12, 2011
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Patent number: 7964597
    Abstract: Disclosed are motilin agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: June 21, 2011
    Assignee: Glaxo Group Limited
    Inventors: Darren Jason Mitchell, Jonathan Thomas Seal, Geoffrey Stemp, Mervyn Thompson, Susan Marie Westaway
  • Patent number: 7964602
    Abstract: The present invention relates to novel biaryl derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: June 21, 2011
    Assignee: Glaxo Group Limited
    Inventors: Gregor James MacDonald, Darren Jason Mitchell, Mervyn Thompson, Susan Marie Westaway
  • Patent number: 7943645
    Abstract: This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: May 17, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, Riccardo Novelli, Roderick Alan Porter
  • Patent number: 7928124
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 19, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Patent number: 7928125
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: April 19, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Patent number: 7919507
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: wherein the substituent variables are as defined herein, and their use as pharmaceuticals.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: April 5, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
  • Patent number: 7897618
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: March 1, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Patent number: 7893090
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 22, 2011
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Patent number: 7799774
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: September 21, 2010
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Patent number: 7754733
    Abstract: Disclosed is a novel crystalline form of topotecan monohydrochloride pentahydrate, which is a pentahydrate of 10-[(dimethylamino)methyl]4-ethyl-4,9-dihydroxy-1H-pyrano[3?,4?:6,7]indolizino[1,2-b]quinoline-3,14(4H, 12H)dione monohydrochloride, corresponding pharmaceutical compositions, methods preparation and/or use thereof to treat anti-viral and/or cancer related diseases.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: July 13, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Philip C. Dell'orco, Ann Marie Diederich, Qiaogong Su, Jeffery Lee Wood
  • Patent number: 7741329
    Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: wherein the substituent variables are as defined herein, and their use as pharmaceuticals.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 22, 2010
    Assignee: SmithKline Beecham Limited
    Inventors: Clive Leslie Branch, Steven Coulton, Amanda Johns, Christopher Norbert Johnson, Roderick Alan Porter, Geoffrey Stemp, Kevin Thewlis
  • Patent number: 7700599
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the GPR38 receptor.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: April 20, 2010
    Assignee: Glaxo Group Limited
    Inventors: Mervyn Thompson, Susan Marie Westaway
  • Patent number: 7601837
    Abstract: The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: October 13, 2009
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, David R Witty
  • Patent number: 7560586
    Abstract: Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: July 14, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Scott K. Thompson, Lara S. Kallander, Chun Ma, Joseph Marino, Dennis Lee
  • Patent number: 7470710
    Abstract: This invention relates to N-aroyl cyclic amine derivatives of formula (I), wherein X represents a bond, oxygen, NR3 or a group (CH2), wherein n represents 1, 2 or 3; Y represents CH2, CO, CH(OH), or CH2CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar2 represents an optionally substituted phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: December 30, 2008
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Clive Leslie Branch, Wai Ngor Chan, Amanda Johns, Christopher Norbert Johnson, David John Nash, Riccardo Novelli, Jean-Pierre Pilleux, Roderick Alan Porter, Rachel Elizabeth Anne Stead, Geoffrey Stemp
  • Patent number: 7468367
    Abstract: This invention relates to heterocyclic substituted ethylene diamine derivatives and their use as pharmaceuticals.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: December 23, 2008
    Assignee: Smithkline Beecham p.l.c.
    Inventors: Steven Coulton, Amanda Johns, Roderick Alan Porter
  • Patent number: 7439243
    Abstract: Disclosed are quinoline compounds of formula (I) having pharmacological activity, processes for their preparation, compositions containing them, and methods for the treatment of CNS and other disorders.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: October 21, 2008
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, Stephen Frederick Moss, David R Witty